03.12.26 -- 9 Pharma Trends To Watch In 2026

BioBridge Global faced challenges with paper-heavy processes that risked errors and delays. Discover how digital solutions streamlined their operations and improved regulatory efficiency.

With a partner who understands the science, the regulations, and the real-world demands of dosing children, development can move faster, smarter, and with greater confidence

Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.

Achieve seamless scale-up and process versatility by utilizing multi-shaft mixing technology. Balance high-shear dispersion with vacuum integration to optimize complex formulations.

Explore the development of high-quality, child-friendly oral formulations, as well as the new testing requirements for impurities and innovative approaches to creating age-appropriate medications.

Learn about the viscosity-driven limits of dye ingress testing, translating qualitative constraints into a quantitative feasibility boundary shaped by defect size, pressure behavior, and plunger mechanics.

Accurate PCD configuration ensures sterility assurance. Find out how to align validation strategies with ISO standards, optimize cycle efficiency, and select the right BI format for EO sterilization success.

Traditional drug models fail to predict performance in human skin. Advanced, multifactorial ex vivo disease models directly address inflammation and infection to de-risk formulation development.

Examine facility cleaning, monitoring, and disinfection strategies to meet regulatory standards, emphasizing planning, stakeholder involvement, testing, documentation, and continuous improvement.

Overcoming development complexity requires robust process safety. Solutions can safely scale challenging reactions, like click chemistry and cryogenic organometallics, improving efficiency.

Small-scale downstream studies play a critical role in enabling efficient, low-risk tech transfer for biologics development.

See how innovative and safer synthetic strategies can streamline the manufacture of Upadacitinib while addressing the complexity and safety challenges inherent in its key intermediates.

Uncover how a biodegradable polymer platform that is compatible with many substrates can enable several applications as a drug eluting carrier with a wide variety of APIs.

By rethinking cleanroom requirements and reducing resource-heavy sterilization steps, manufacturers can significantly lower their Environmental Cost of Ownership and futureproof their operations.